---
schema_version: "secwatch.filing_event.v1"
accession: "0001267602-24-000016"
form_type: "8-K"
ticker: null
cik: "0001267602"
company_name: "ALIMERA SCIENCES INC"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:11:09.022531+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alimera Q4 net revenue +88% to $26.3M, positive EBITDA; guides >$105M for 2024; expands credit line by $5M

## Summary
- Q4 net revenue $26.3M (+88% YoY); full year $80.8M (+49%); net loss flat at $3.8M.
- Q4 adjusted EBITDA positive $5.0M vs $(1.2M) loss YoY; full year $8.7M vs $(7.9M) loss.
- Raises 2024 revenue guidance to >$105M and expects >20% adjusted EBITDA margin.
- U.S. net revenue $19.2M (+104%) driven by YUTIQ; international $7.1M (+52%).
- Amended loan facility: increased from $67.5M to $72.5M, $5M term loan funded; maturity April 2028.

## SEC filing metadata
- accession: 0001267602-24-000016
- form_type: 8-K
- cik: 0001267602
- company_name: ALIMERA SCIENCES INC
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/0001267602-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/alim-20240306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001267602-24-000016
- JSON: https://secwatch.observer/filing/0001267602-24-000016.json
- Plain text: https://secwatch.observer/filing/0001267602-24-000016.txt

## Key facts
- Earnings Releases
  ALIMERA SCIENCES INC reported the fourth quarter and full year ended December 31, 2023 results: revenue Net revenue of $26.3 million up 88% vs. fourth quarter of 2022, net income Net loss of $3.8 million consistent with fourth quarter of 2022. Guidance raised.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: Net revenue of $26.3 million up 88% vs. fourth quarter of 2022
  - Net income: Net loss of $3.8 million consistent with fourth quarter of 2022
  - Guidance: raised
  - Result: reported results
  source text: On March 7, 2024, Alimera issued a press release regarding its results of operations and financial condition for the fourth quarter and full year ended December 31, 2023 as well as recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/0001267602-24-000016-index.htm
- Material Agreements
  ALIMERA SCIENCES INC amended Seventh Amendment with SLR Capital Partners, LLC (effective 2024-03-06).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: SLR Capital Partners, LLC
  - Effective: 2024-03-06
  source text: On March 6, 2024, Alimera Sciences, Inc. (“Alimera”) entered into the Seventh Amendment (the “Amendment”) to its Loan and Security Agreement dated December 31, 2019, with SLR Capital Partners, LLC (“SLR”) as collateral agent, and the lenders party thereto
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000016/0001267602-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.